Flotation

Utec-backed Chiba spinout Autonomous Control Systems Laboratory has filed for an initial public offering on the Tokyo Stock Exchange and plans to list on December 21.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.